Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : HAYATI Journal of Biosciences

Cloning, Expression, and Bioinformatics Modeling of Human Papillomavirus Type 52 L1/L2 Chimeric Protein in Escherichia coli BL21 (DE3) Ikramullah, Muh. Chaeril; Mustopa, Apon Zaenal; Wibawa, Tri; Hertati, Ai; Umami, Rifqiyah Nur; Ratna, Lita Tri; Irawan, Shasmita; Firdaus, Moh Egy Rahman; Darusman, Huda Salahudin
HAYATI Journal of Biosciences Vol. 31 No. 5 (2024): September 2024
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.31.5.891-902

Abstract

Human papillomavirus (HPV) L1 major capsid protein generates a highly immunogenic virus like particles (VLPs), which have been used as the main component of its prophylactic vaccine. However, the neutralizing antibodies against L1 VLPs are mostly type specific and may not be effective to prevent infection from different strains of HPV. On the other hand, HPV L2 minor capsid protein has low antigenic variation, thus can induce cross-neutralization. This study aims to obtain HPV 52 L1/L2 chimeric protein, which is designed based on HPV type 52 as one of the most circulated high-risk types in Indonesia, to develop a broad-spectrum HPV vaccine. Substitution of HPV 52 H4 helix L1 region with an HPV 52 L2 epitope was carried out using overlap extension PCR. HPV 52 L1/L2 chimeric gene was constructed into pET-SUMO expression vector and expressed in Escherichia coli BL21 (DE3). Bioinformatics modeling suggested that L2 epitope was located inside of the loop region in monomer form, and on the contrary, it was located outside of the pentamer surface. Furthermore, B cell and T cell epitopes predictions were conducted using Immune Epitope Database (IEDB) analysis. The B cell epitopes prediction revealed eleven potential epitopes, whereas the T cell epitopes prediction showed seven potential epitopes for each MHC class I and MHC class II. This study showed that HPV 52 L1/L2 chimeric protein has the potential to induce cross-neutralizing antibodies and can be developed as a promising candidate for a new HPV vaccine.
Co-Authors Abdul Rahman Siregar Abdul Rahman Siregar, Abdul Rahman Abu Tholib Aman Adi Sofyan Ansori, Muhammad Ai Hertati, Ai Ali Wardana Anika Prastyowati, Anika Apon Zaenal Mustopa Arief Mulyono Arifah Khusnuryani Aris Haryanto Aris Haryanto Arum Sih Joharina Boy Bachtiar Cita Rosita Sigit Prakoeswa Daniwijaya, M Edwin Widyanto Diani Mentari Diptyanusa, Ajib Domas Fitria Widyasari Erni Martani Farahannisaa, Kintan Adelia Farida Dwi Handayani Farida J. Rachmawaty Farida J. Rachmawaty, Farida J. Febe, Ester Firdaus, Moh Egy Rahman Frutos, Roger Gunawan Gunawan Gunawan Madyono Putro Hakim, Mohamad Saifudin Hamidah, Berliana Hardyanto Soebono Haryanto, Darban Hayani Anastasia Hera Nirwati Huda Shalahudin Darusman I Kadek Mulyawan Ikramullah, Muh. Chaeril Intan Berlianty Irawan, Shasmita JAKA WIDADA Laksmi Wulandari Maguin, Sylvie Mahardika Agus Wijayanti Marsetyawan H.N.E. Soesatyo Marsetyawan H.N.E. Soesatyo, Marsetyawan H.N.E. Mirtani Naima Mubasysyir Hasanbasri Mulyawan, I Kadek Munawir Sazali Naima, Mirtani Nastiti Wijayanti Nastiti Wijayanti Nastiti Wijayanti Ning Rintiswati Ning Rintiswati Novriana, Riska Nurhaida Widiani Ova Emilia Pakpahan, Cennikon Pascawati, Nur Alvira Puteri, Rr. Astrid Aulia Artiono R.C. Hidayat Soesilohadi Rania Ayu Aziza Ratna, Lita Tri Rifqiyah Nur Umami, Rifqiyah Nur Riska Wulansari Ristiyanto Ristiyanto Roger Frutos S Siswanto S. Sutaryo Sadi Setyawan Budiharta Supargiono Supargiono Suratna, Suratna Sutaryo1 S, Sutaryo1 Sylvie Maguin Tri Baskoro Tunggul Satoto Tri Rini Nuringtyas Utomo, Humam Santosa Wardana, Ali Widya Asmara Wirastuti, Fita Wulansari, Riska Yati Soenarto Yundari, Yundari